Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

October 09, 2019

Patients with neuroendocrine tumors that have metastasized to the liver derive clinical benefit from locoregional therapies, but treatment guidelines for employing these strategies must be more fully developed.

October 08, 2019

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses agents in development in advanced pancreatic cancer.

September 27, 2019

David H. Ilson, MD, PhD, discusses the utility of TAS-102 in gastric and GEJ adenocarcinoma as well as other encouraging research in these spaces.

September 25, 2019

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

September 20, 2019

Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.

September 18, 2019

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).

September 17, 2019

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

September 03, 2019

Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.

August 30, 2019

Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.

August 08, 2019

Charles M. Rudin, MD, PhD, the Sylvia Hassenfeld Chair in Lung Cancer Research, chief, Thoracic Oncology, co-director, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the current landscape of immunotherapy in lung cancer and how he expects the treatment to expand.

July 31, 2019

David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.

July 30, 2019

C. Ola Landgren, MD, PhD, shares his expert insight on recent shifts in multiple myeloma management.

July 11, 2019

Ariela Noy, MD, discusses a phase II trial of devimistat in Burkitt lymphoma and other lymphomas, and describes the unique mechanism of action of the agent.

June 26, 2019

Mark G. Kris, MD, discusses the latest data with osimertinib (Tagrisso) and shared unanswered questions that remain in EGFR-positive non–small cell lung cancer.

June 25, 2019

Daniel Gomez, MD, provides insight on the different treatment approaches under exploration for patients with oligometastatic disease.

June 13, 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses methods for predicting benefit with osimertinib (Tagrisso) in patients with EGFR-positive non–small cell lung cancer (NSCLC).

June 12, 2019

Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses future treatment strategies in early-stage non–muscle invasive bladder cancer.

May 24, 2019

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the frontline treatment of patients with newly diagnosed ovarian cancer.

May 18, 2019

Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.

May 15, 2019

Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing work with immunotherapy in patients with advanced ovarian cancer.